PDCD1 and non-small cell lung carcinoma: Some studies have pre-empted the publication of interim PFS data (e.g., RATIONALE 304 or RATIONALE 307) to give a new perspective on the NSCLC patients using PD-1/PD-L1 inhibitors, and their immature OS data may have some impact on the results of our network meta-analysis.